Skip to content
Shuttingdown

Liminatus Pharma, Inc.

Biological Products, (No Diagnostic Substances) · CERRITOS

Distress signal

Moderate confidence (50%)

Updated Oct 18, 2026, 12:04 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: Liminatus Pharma, Inc. received a delisting notice from its exchange (Sep 24, 2026)

Timeline

Every material event, newest first. History is never overwritten.

  1. Liminatus Pharma, Inc. received a delisting notice from its exchange

    Sep 24, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on January 15, 2026 Liminatus Pharma, Inc. (the Company ) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that the closing bid price of the Company s common stock had been below $1.00 for 30 consecutive business days, and, consequently, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the applicable minimum bid price requirement for The Nasdaq Global Market). Followi…”

  2. Liminatus Pharma, Inc. received a delisting notice from its exchange

    Aug 18, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on November 19, 2025, Liminatus Pharma, Inc., a Delaware corporation (the Company ), received notices from The Nasdaq Stock Market ( Nasdaq ) indicating that the Company was no longer in compliance with the following continued listing requirements of The Nasdaq Global Market: (i) Listing Rule 5450(b)(2)(A), which requires a listed company to maintain a minimum Market Value of Listed Securities ( MVLS ) of $50,000,000 (the MVLS Rule ) and (ii) Listing Rule 5450(…”

  3. Liminatus Pharma, Inc. received a delisting notice from its exchange

    Jul 20, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on January 15, 2026, Liminatus Pharma, Inc. (the Company ) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the Bid Price Rule ) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules,…”

  4. Liminatus Pharma, Inc. received a delisting notice from its exchange

    May 20, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed in the Current Report on Form 8-K filed on November 25, 2025 with the Securities and Exchange Commission (the SEC ), on November 19, 2025, Liminatus Pharma, Inc. (the Company ) received notices from The Nasdaq Stock Market LLC ( Nasdaq ), indicating that the Company s listed securities failed to comply with the $50,000,000 market value of listed securities (MVLS) requirement for continued listing in accordance with Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS Ru…”

  5. Liminatus Pharma, Inc. received a delisting notice from its exchange

    Jan 15, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 15, 2026, Liminatus Pharma, Inc. (the Company ) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the Bid Price Rule ) which requires listed securities to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the…”

Company information

Founded
—
Employees (estimate)
—
Industry
Biological Products, (No Diagnostic Substances)
Subindustry
—
Listing
SEC lists the tickers LIMN and LIMNW on Nasdaq.
SEC CIK
0001971387
Website
—
LinkedIn
—
Headquarters
CERRITOS
Also known as
Iris Parent Holding Corp.
Legal entities
Liminatus Pharma, Inc.

Sources

Every material source used to build this profile.

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on January 15, 2026 Liminatus Pharma, Inc. (the Company ) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that the closing bid price of the Company s common stock had been below $1.00 for 30 consecutive business days, and, consequently, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the applicable minimum bid price requirement for The Nasdaq Global Market). Followi…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed in the Current Report on Form 8-K filed on November 25, 2025 with the Securities and Exchange Commission (the SEC ), on November 19, 2025, Liminatus Pharma, Inc. (the Company ) received notices from The Nasdaq Stock Market LLC ( Nasdaq ), indicating that the Company s listed securities failed to comply with the $50,000,000 market value of listed securities (MVLS) requirement for continued listing in accordance with Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS Ru…
    View source record

  • SEC Company Submissions (TIER 1 · UNVERIFIED)

    Liminatus Pharma, Inc. — Biological Products, (No Diagnostic Substances) (SIC 2836) — CERRITOS, CA
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 15, 2026, Liminatus Pharma, Inc. (the Company ) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the Bid Price Rule ) which requires listed securities to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on November 19, 2025, Liminatus Pharma, Inc., a Delaware corporation (the Company ), received notices from The Nasdaq Stock Market ( Nasdaq ) indicating that the Company was no longer in compliance with the following continued listing requirements of The Nasdaq Global Market: (i) Listing Rule 5450(b)(2)(A), which requires a listed company to maintain a minimum Market Value of Listed Securities ( MVLS ) of $50,000,000 (the MVLS Rule ) and (ii) Listing Rule 5450(…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on January 15, 2026, Liminatus Pharma, Inc. (the Company ) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the Bid Price Rule ) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules,…
    View source record

Status history

Every derived status, with the rule that produced it.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:30 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:13 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 12, 2026, 12:15 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:27 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.